SAN FRANCISCO--(BUSINESS WIRE)--FibroGen, Inc., today announced proof-of-principle for oral anemia therapy FG-4592, a hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor (PHI), in end-stage ...
Researchers have found evidence that could help explain why some anemic CKD patients are resistant to treatment with erythropoiesis stimulating agents. Patients on high-dose ESA had significantly ...
In anemic kidney disease patients with cancer, reviewers suggest using ESA to minimize symptoms without exceeding a hemoglobin target of 10 g/dL. Current guidelines have not fully addressed the use of ...
Please provide your email address to receive an email when new articles are posted on . Patients switched to oral vadadustat had hemoglobin levels similar to those on a long-acting ...
In a Japanese study, approximately 1 in 8 CKD patients with anemia failed to respond to darbepoetin alfa therapy. Specific factors may predict better initial response to darbepoetin alfa in patients ...
Expert panelists discuss when it’s appropriate to consider or continue ESA therapy or blood transfusions in patients with MDS. Bruce Feinberg, DO: Amer, invariably, there are patients who aren’t going ...
A decade of globalization: Trends in participation of investigators from lower-resource economies in phase III lung cancer trials. Background: Two ESAs (darbepoetin alfa, epoetin alfa) are ...
There are more than 700,000 prevalent cases of end-stage kidney disease in the United States, which is increasing by approximately 20,000 cases per year. 1 Peritoneal dialysis is a home renal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback